Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations
International Journal of Molecular Sciences · 25.02.2025 · 26 (5) · 2012
DOI: 10.3390/ijms26052012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.02.2025. Verfasst von Rebeca Santamarina-Fernández und 5 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Vaccine Development, Pseudomonas Vaccines. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, SERGAS-Galician Healthcare Service, CIBERINFEC.
Abstract (Originalsprache)
Pseudomonas aeruginosa is an opportunistic pathogen with a multidrug-resistant profile that has become a critical threat to global public health. It is one of the main causes of severe nosocomial infections, including ventilator-associated pneumonia, chronic infections in patients with cystic fibrosis, and bloodstream infections in immunosuppressed individuals. Development of vaccines against P. aeruginosa is a major challenge owing to the high capacity of this bacterium to form biofilms, its wide arsenal of virulence factors (including secretion systems, lipopolysaccharides, and outer membrane proteins), and its ability to evade the host immune system. This review provides a comprehensive historical overview of vaccine development efforts targeting this pathogen, ranging from early attempts in the 1970s to recent advancements, including vaccines based on novel proteins and emerging technologies such as nanoparticles and synthetic conjugates. Despite numerous promising preclinical developments, very few candidates have progressed to clinical trials, and none have achieved final approval. This panorama highlights the significant scientific efforts undertaken and the inherent complexity of successfully developing an effective vaccine against P. aeruginosa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, 15006 A Coruña, Spain.
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Área de Medicamentos Biológicos, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), 28022 Madrid, Spain.
- Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Universidad de A Coruña, 15006 A Coruña, Spain.
ORCID-Profile: Patricia García, Miriam Moscoso, Germán Bou
Förderung
- Instituto de Salud Carlos III
- SERGAS-Galician Healthcare Service
- CIBERINFEC
- Ministry of Economy and Competitiveness
- Conselleria de Cultura
Zitieren
APA
Santamarina-Fernández, R., Fuentes-Valverde, V., Silva-Rodríguez, A., García, P., Moscoso, M., & Bou, G. (2025). Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations. International Journal of Molecular Sciences, 26(5), 2012. https://doi.org/10.3390/ijms26052012
Vancouver
Santamarina-Fernández R, Fuentes-Valverde V, Silva-Rodríguez A, García P, Moscoso M, Bou G. Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations. International Journal of Molecular Sciences. 2025;26(5):2012. doi:10.3390/ijms26052012
BibTeX
@article{SantamarinaFernndez2025,
author = {Santamarina-Fernández, Rebeca and Fuentes-Valverde, Víctor and Silva-Rodríguez, Alis and García, Patricia and Moscoso, Miriam and Bou, Germán},
title = {Pseudomonas aeruginosa Vaccine Development: Lessons, Challenges, and Future Innovations},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {5},
pages = {2012},
doi = {10.3390/ijms26052012}
}
EUVIMED